
Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.
Anthelmintics, Giardiasis, Protozoan Infections, Antiparasitic Agents, Antiprotozoal Agents, Drug Resistance, Helminthiasis, Amebiasis, Trematode Infections, Cestode Infections, Malaria, Trypanosomiasis, African, Parasitic Diseases, Humans, Chagas Disease, Nematode Infections, Leishmaniasis, Toxoplasmosis
Anthelmintics, Giardiasis, Protozoan Infections, Antiparasitic Agents, Antiprotozoal Agents, Drug Resistance, Helminthiasis, Amebiasis, Trematode Infections, Cestode Infections, Malaria, Trypanosomiasis, African, Parasitic Diseases, Humans, Chagas Disease, Nematode Infections, Leishmaniasis, Toxoplasmosis
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 114 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
